- Conditions
- Overweight or Obesity and Elevated Liver Fat
- Interventions
- Maridebart cafraglutide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 23
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more
Location Directory
Clinical trials in Phoenix, Arizona
This page shows live ClinicalTrials.gov search results for Phoenix, Arizona, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1813
Shown on this page
12
Current sort
Recently updated
Location scope
Phoenix, AZ
Filters apply within this location only.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Showing 445–456 of 1,813 matching trials in Phoenix, AZ.
Indexed local directory records.
Institutions in Phoenix
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Stored official records
Open in full search- Conditions
- Irritability Associated With Autism Spectrum Disorder
- Interventions
- KarX-EC, KarXT, KarXT + KarX-EC Matching Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Glendale, California • Los Angeles, California + 19 more
- Conditions
- Adenocarcinoma of Esophagus, Biliary Tract Carcinoma, Bladder Cancer, Gastric Adenocarcinoma, Gastroesophageal Cancer (GC), Mesothelioma, NSCLC Adenocarcinoma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Peritoneal Mesothelioma, Pleural Mesothelioma, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC)
- Interventions
- IDE397, IDE892
- Drug
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 23
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more
- Conditions
- SARS-CoV-2
- Interventions
- Placebo, mRNA-1273, mRNA-1283
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years to 64 Years
- Enrollment
- 30,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 150
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more
- Conditions
- Biliary Tract Cancer
- Interventions
- Durvalumab, Gemcitabine/Cisplatin, Rilvegostomig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Pirtobrutinib, Tacabrutideg
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 42 more
- Conditions
- Arthritis, Gouty, Gout, Gout Chronic, Hyperuricemia
- Interventions
- AR882 50 mg, AR882 75 mg, Placebo
- Drug
- Lead sponsor
- Arthrosi Therapeutics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 866 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 74 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Placebo, Remibrutinib (Blinded), Remibrutinib (Open Label)
- Other · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 18 more
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- RYZ801, RYZ811
- Drug · Diagnostic Test
- Lead sponsor
- RayzeBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Orange, California + 10 more
- Conditions
- Major Depressive Disorder
- Interventions
- CYB003, Placebo, Psychological Support
- Drug · Behavioral
- Lead sponsor
- Cybin IRL Limited
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bellflower, California + 35 more
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable, Pancreatic Cancer Stage, Pancreatic Cancer Stage 0, Pancreatic Cancer Stage I, Pancreatic Cancer Stage II, Pancreatic Cancer Stage III, Pancreatic Cancer, Adult, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms
- Interventions
- PANcreatic cancer Exosome Early detectiON (PANXEON)
- Diagnostic Test
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2030
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Monrovia, California + 8 more
- Conditions
- Plaque Psoriasis
- Interventions
- Deucravacitinib, Deucravacitinib Matching Placebo, JNJ-77242113, JNJ-77242113 Matching Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Encinitas, California • Encino, California + 32 more